



MOLECULAR TEMPLATES

Company Overview

Molecular Templates is focused on the discovery, development, and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases.

Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study

Dec 21 2020, 4:30 PM EST

Molecular Templates to Participate in Upcoming Virtual Investor Conferences

Nov 16 2020, 4:30 PM EST

Molecular Templates, Inc. Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

Nov 5 2020, 4:30 PM EST

Stock Overview

Symbol	MTEM
Exchange	Nasdaq
Market Cap	552.1m
Last Price	\$11.05
52-Week Range	\$7.52 - \$19.13

01/15/2021 04:00 PM EST

Investor Relations

Adam Cutler
Chief Financial Officer
T: 862-204-4006
adam.cutler@mtem.com

Management Team

Eric Poma, Ph.D.

Chief Executive Officer & Chief Scientific Officer

Jason Kim

President & Chief Operating Officer

Roger Waltzman, M.D.

Chief Medical Officer

Adam Cutler

Chief Financial Officer

Jack Higgins, Ph.D.

Chief Development Sciences Officer

Betty Chang, Ph.D.

Senior Vice President, Translational Research and Early Development

Michael Dowd

Senior Vice President, Project & Alliance Management

Megan Filoon

Corporate Counsel

Ryan Hawkins

Senior Vice President and Head of Manufacturing

Dennis Jones

Senior Vice President, Quality

Sean McLennan

Senior Vice President, Finance and Corporate Controller

Joseph Phillips, Ph.D.

Senior Vice President and Head of CMC Development

Kristen Quigley

Senior Vice President, Clinical Operations

Molecular Templates, Inc.

9301 Amberglen Blvd
Suite 100
Austin, TX 78729

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the

property of their respective companies.